Boston Scientific today revealed results of a comprehensive survey which shows the true burden of severe asthma and the daily challenges faced by people with asthma in Europe. Uncovering Asthma, a...

New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more...

Results from clinical trials evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System continue to show this advanced transcatheter aortic valve implantation (TAVI) therapy delivers...

Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting...

Boston Scientific welcomes the updated ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death announced during ESC Congress 2015, the...

Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...

Boston Scientific Corporation (NYSE: BSX) has closed on the previously announced agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to purchase the American Medical Systems (AMS)...

First Guidewire Designed Specifically for TAVI/R Now Sized for Smaller Ventricles Boston Scientific (NYSE: BSX) announces CE Mark and FDA clearance for the Safari2™ Pre-Shaped Guidewire, a new...

MILAN, Italy, June 23, 2014 – Attendees of EHRA EUROPACE-CARDIOSTIM 2015, a global medical conference held recently in Milan, Italy, have selected the EMBLEM™ S-ICD System as the most...

Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for...